



# THE IHS PRIMARY CARE PROVIDER

*A journal for health professionals working with American Indians and Alaska Natives*



August 2017

Volume 42 Number 8



*Indian Health Service  
National Pharmacy and Therapeutics Committee  
Diabetes Treatment Overview  
NPTC Formulary Brief  
August 2017*



**Background:**

Diabetes mellitus is the seventh leading cause of death in the United States with a point-prevalence in 2014 of 29.1 million persons living with the disease.<sup>1</sup> Type 2 diabetes is by far the leading subtype. Health disparities related to diabetes in Indian Country include not only a substantially higher prevalence among both adults and adolescents but also increased morbidity and mortality compared to the general population.

**Discussion:**

Diabetes treatment goals include a reduction in both microvascular and macrovascular complications as well as death from all causes. Intermediate, or so-called “surrogate” outcomes, include measurable declines in hemoglobin A1c, weight, and systolic blood pressure. Cardiovascular complications of diabetes result from a complex milieu of pro-inflammatory variables linked both directly and indirectly to insulin resistance. The effectiveness of multiple anti-hyperglycemic agents to reduce both microvascular and macrovascular complications have been demonstrated in studies of older and newer agents. Generally missing are well-designed, large, head-to-head studies adequately powered to measure the comparative effectiveness of the different agents, especially the newer ones, in improving clinical outcomes.

It is important to note that the basis of diabetes treatment for all patients is lifestyle therapy. This includes nutrition and behavioral support, regular physical activity, weight management, tobacco cessation, and good sleep hygiene.

**Findings:**

During the August 2017 meeting, the NPTC reviewed recent guidelines from the American Diabetes Association (ADA), the United Kingdom’s National Institute for Health and Care Excellence (NICE), the American Association of Clinical Endocrinologists (AACE), and the American College of Physicians (ACP).<sup>3-6</sup>

The current ADA treatment recommendations represent the “patient centered approach” advocated in its joint position statements published in 2012 and 2015 with the European Association for the Study of Diabetes.<sup>2-3</sup> The 2012 statement was less prescriptive than prior recommendations. This was prompted primarily due to an increasing number of available anti-hyperglycemic drugs and growing uncertainty among providers regarding the proper selection and sequence of medications. Because of an identified lack of comparative effectiveness research and unclear impact on long-term outcomes, an individualized treatment strategy without a specified

**In this Issue...**

41 NPTC Formulary Brief: Diabetes Treatment Overview

43 Electronic Subscriptions Available

hierarchy of meds has been advocated. In its 2015 position statement, the ADA identified the need for studies of the cardiovascular impact of the various newer glucose lowering therapies.<sup>3</sup> It also noted the anticipated publication in 2020 of the comparative effectiveness study, The Glycemia Reduction Approaches in Diabetes (GRADE), currently underway to assess long-term outcomes of multiple agents after failure of metformin monotherapy.

Various glycemic control targets are advocated by current guidelines and range from a hemoglobin A1c of 6.5 to 8.0% depending on patient characteristics. Individualized targets are advocated, with more stringent goals generally reserved for younger patients, those newly diagnosed without significant comorbidities, and those least at risk of significant hypoglycemia. Less stringent targets are indicated for older persons with significant comorbidities, history of severe hypoglycemia, those with limited life expectancy, and those with longstanding diabetes that has been difficult to control.

The ADA stratifies recommendations for the initiation of therapy based on the level of the hemoglobin A1c.<sup>3</sup> Metformin monotherapy is recommended for those with a hemoglobin A1c value less than or equal to 9.0% whereas dual therapy with metformin and a second line agent is recommended for those with an initial hemoglobin A1c of 9.1 to 9.9%. For those with an initial hemoglobin A1c over 10.0%, consideration of combination injection therapy is advocated, such as basal insulin plus either rapid acting insulin or a glucagon-like peptide-1 (GLP-1) receptor agonist. Quarterly reassessment with intensification of therapy is recommended for those not at goal.

Dual therapy is warranted for those who fail to meet an appropriate glycemic control target with metformin monotherapy following a period of initial treatment.<sup>3</sup> Dual therapy consists of metformin plus one of a number of second-line agents including a sulfonylurea, thiazolidinedione, dipeptidyl peptidase-4 (DPP-4) inhibitor, sodium-glucose co-transporter 2 inhibitor, GLP-1 receptor agonist, or basal insulin. According to the ADA guideline, there is no hierarchy of preference among these agents and the choice of agent should be based on individual patient and disease-specific factors. For those not meeting their glycemic target at three months, triple therapy is recommended.

Triple therapy consists of metformin plus any two of the other agents with the exception of a combination of a DPP-4 inhibitor and GLP-1 agonist.<sup>3</sup> Again, there is no hierarchy of preference among the agents and choice should be individualized to the patient. For those still not meeting their goal at three months, combination injection therapy is advocated. According to the ADA guideline, combination injection therapy consists of metformin plus basal insulin and either pre-prandial rapid acting insulin or a GLP-1 receptor agonist or alternately, a switch from basal to pre-mixed insulin. If goals are still not met, basal-bolus or pre-mixed insulin three times daily is recommended. In deference to the complexity of treatment regimens and the resulting impact on medication adherence, the ADA advocates discontinuation of oral anti-hyperglycemic medications, with the exception of metformin, for those patients on combination injection therapy.

The NICE and AACE guidelines, also released in 2017, take a similar approach to medication management, with the exception that in the AACE guideline, specific treatments are ordered according to a recommended hierarchy of use based on expert consensus.<sup>4-5</sup>

Following a systematic review of the comparative effectiveness and risks of the various oral agents for the treatment of Type 2 Diabetes, the ACP updated its guidelines with the recommendation, based on strong evidence, to prescribe metformin when medication is needed for glycemic control.<sup>6</sup> Based on weak evidence, a combination of metformin and any other oral agent was recommended (when needed for better glycemic control), considering individual medication characteristics.

### **Conclusions:**

A variety of drugs are available with similar efficacy for glycemic control and a range of both side effects and effectiveness for short- and long-term clinical outcomes. There is limited clinical trial comparison data to support superiority, especially among the newer agents. Most guidelines do not support a hierarchy among second and third line medication options. Contemporary guidelines do advocate individualized glycemic control targets and treatment strategies as well as a step-wise approach to therapy. Finally, metformin is both the best initial treatment for Type 2 Diabetes and should optimally be included in all combination treatment plans, except when contraindicated or not tolerated.

*For questions about this document, please contact the NPTC at [IHSNPTC1@ihs.gov](mailto:IHSNPTC1@ihs.gov). For more information about the NPTC, please visit the [NPTC website](#).*

## **References:**

1. Centers for Disease Control and Prevention. [National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014](#). Atlanta: U.S. Department of Health and Human Services; 2014.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. [Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association and the European Association for the Study of Diabetes](#). *Diabetes Care*. 2012; 35:1364-1379.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. [Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes](#). *Diabetes Care*. 2015; 38:140-149.
4. National Institute for Health and Care Excellence. [Type 2 Diabetes in Adults: Management](#). Dec 2015; Update May 2017.
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. [CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM](#). *Endocr Pract*. 2017; 23(2):207-238.
6. Qaseem A, Barry MJ, Humphrey LL, et al. [Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update from the American College of Physicians](#). *Ann Intern Med*. 2017; 166(4):279-290.

## **Electronic Subscription Available**

You can subscribe to The Provider electronically. Any reader can now request that he or she be notified by e-mail when the latest issue of The Provider is available on the Internet. To start your electronic subscription, go to The Provider website (<http://www.ihs.gov/Provider>). Click on the “subscribe” link; note that the e-mail address from which you are sending this is the e-mail address to which the

electronic notifications will be sent. Do not type anything in the subject or message boxes; simply click on “send.” You will receive an e-mail from LISTSERV.IHS.GOV; open this message and follow the instruction to click on the link indicated. You will receive a second e-mail from LISTSERV.IHS.GOV confirming you are subscribed to The Provider listserv.



THE IHS PROVIDER is published monthly by the Indian Health Service Clinical Support Center (CSC). Telephone (602) 364-7777; fax: (602) 364-7788; email:[the.provider@ihs.gov](mailto:the.provider@ihs.gov). Previous issues of THE PROVIDER (beginning with the 1997 Volume) can be found online at <https://www.ihs.gov/provider>.

**Opinions expressed in articles are those of the authors and do not necessarily reflect those of the Indian Health Service or the Editors.**

**Circulation:** THE PROVIDER (ISSN 1063-4398) is distributed on the CSC website to health care providers working for the IHS and tribal health programs, to medical schools throughout the country, and to health professionals working with or interested in American Indian and Alaska Native health care. If you would like to subscribe, go to <https://www.ihs.gov/provider>.

**Publication of articles:** Manuscripts, comments, and letters to the editor are welcome. Items submitted for publication should be no longer than 3000 words in length, typed, double-spaced, and conform to manuscript standards. PC-compatible word processor files are preferred. Manuscripts may be received via e-mail.

Authors should include references. All manuscripts are subject to editorial and peer review. Responsibility for obtaining permission from appropriate tribal authorities and Area Publications Committees to publish manuscripts rests with the author. For those that would like more information, please contact the CSC directly or visit our website at <http://www.ihs.gov/csc>.